Ibrahim N, El Said H, Choukair A. Zinc carnosine-based modified bismuth quadruple therapy vs standard triple therapy for Helicobacter pylori eradication: A randomized controlled study. World J Clin Cases 2022; 10(1): 227-235 [PMID: 35071521 DOI: 10.12998/wjcc.v10.i1.227]
Corresponding Author of This Article
Nour Ibrahim, MD, Research Fellow, Faculty of Medical Sciences, Lebanese University, Old Saida Road Street, Hadath Area, Beirut 0000, Lebanon.nouribrahim5@hotmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Randomized Controlled Trial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jan 7, 2022; 10(1): 227-235 Published online Jan 7, 2022. doi: 10.12998/wjcc.v10.i1.227
Zinc carnosine-based modified bismuth quadruple therapy vs standard triple therapy for Helicobacter pylori eradication: A randomized controlled study
Nour Ibrahim, Hassan El Said, Ali Choukair
Nour Ibrahim, Faculty of Medical Sciences, Lebanese University, Beirut 0000, Lebanon
Hassan El Said, Department of Biological and Chemical Sciences, School of Arts and Sciences, Lebanese International University, Beirut 0000, Lebanon
Ali Choukair, Department of Gastroenterology, Clemenceau Medical Center, Dubai 00000, United Arab Emirates
Author contributions: Choukair A designed the study, collected the data and wrote the first draft of the manuscript; Ibrahim N analyzed the data and contributed to the manuscript writing; all authors critically revised the manuscript and read and approved the final version of the manuscript.
Supported bySynergy Group
Institutional review board statement: This study was reviewed and approved by the Clinical Research Ethics Committee of NMC specialty hospital.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Nour Ibrahim, MD, Research Fellow, Faculty of Medical Sciences, Lebanese University, Old Saida Road Street, Hadath Area, Beirut 0000, Lebanon.nouribrahim5@hotmail.com
Received: June 25, 2021 Peer-review started: June 25, 2021 First decision: July 27, 2021 Revised: August 7, 2021 Accepted: November 28, 2021 Article in press: November 28, 2021 Published online: January 7, 2022 Processing time: 187 Days and 14.9 Hours
ARTICLE HIGHLIGHTS
Research background
The rate of resistance of Helicobacter pylori (H. pylori) infection has been increasing worldwide. It is necessary to consider new alternatives to overcome the failure of H. pylori eradication rate.
Research motivation
There is shortage in reports on whether zinc carnosine is effective against H. pylori eradication.
Research objectives
Investigate the effect of triple therapy (TT) vs modified bismuth quadruple therapy against H. pylori eradication rate.
Research methods
Ninety-two patients with dyspepsia symptoms and positive 13C-urea breath test were randomly assigned in to the following two groups: TT group treated for 14 d using esomeprazole (40 mg twice daily), amoxicillin (1 g twice daily) and clarithromycin (500 mg twice daily). On the other hand, the modified bismuth quadruple therapy fortified with zinc carnosine was prescribed a 10-d of TT in addition to bismuth subcitrate (240 mg twice daily) and zinc carnosine (75 mg twice daily). A 13C-urea breath test was repeated after 4 wk from the completion of the eradication therapy.
Research results
The eradication rate was higher in the modified bismuth quadruple therapy group compared to that of the standard TT group (P = 0.003).
Research conclusions
Ten-day modified bismuth quadruple therapy is a safe and effective regimen for eradicating H. pylori infection.
Research perspectives
The first-line therapy for H. pylori eradication should be re-evaluated. Alternative regimens with higher eradication of H. pylori should be further investigated.
